Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BRAVERY

Financiado

Cerrado

Dual Stimuli-Responsive Nanoparticles to Achieve Brain Multi-drugs Delivery Impr...

Dual Stimuli-Responsive Nanoparticles to Achieve Brain Multi-drugs Delivery Improving the Treatment of Neurodegenerative Disorders Leading to disability and morbidity, neurodegenerative disorders (NDs) have a profound socio-economic impact. Given the aging of the population, they are raising remarkable concerns. Several active compounds for NDs treatment show... ver más

31/12/2026

IRFMN

Presupuesto desconocido

Líder del proyecto

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2025-01-01

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

IRFMN

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-127983OB-C22 EVALUACION IN VITRO E IN VIVO DE NUEVOS NANOPORTADORES PARA... 104K€ Cerrado

RTI2018-098027-B-C22 ESTUDIOS IN VITRO E IN VIVO DE NUEVOS NANOVEHICULOS PARA TER... 73K€ Cerrado

Smart Nanoparticles 4D Brain-Targeting Nanomedicines for Treating Neurodegenerat... 2M€ Cerrado

NANONEUROPROTECTION Nanomaterials for treatment of neurodegenerative disorders 300K€ Cerrado

SAF2017-84407-R OPTIMIZACION DE UN SISTEMA DE LIBERACION NANOTERAPEUTICA BAS... 50K€ Cerrado

NANOASSAY Development of a multiplex nanofluidic assay for selective d... 169K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2025-01-01
Fecha Fin: 2026-12-31

Líder del proyecto

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Leading to disability and morbidity, neurodegenerative disorders (NDs) have a profound socio-economic impact. Given the aging of the population, they are raising remarkable concerns. Several active compounds for NDs treatment showed promising results in-vitro but failed in-vivo due to unfavorable biodistribution and limited biocompatibility. The nanocarriers (NC) proposed in the last decade have certainly improved brain delivery of active compounds, however, the limited bioavailability of the drug and biocompatibility issues make NDs treatment still a hot topic in neuroscience. With BRAVERY, I aim to achieve the spatiotemporal controlled drug release improving the bioavailability of neuroactive compounds in the brain without causing neurotoxicity. To do so, I propose to develop a novel biocompatible multi-drug NC capable of efficiently targeting the brain and releasing the loaded drugs in a controlled manner in response to specific stimuli, after intranasal administration. The proposed NC has three fundamental features: 1) It is mucoadhesive; 2) It degrades in response to two specific stimuli that allow achieving a spatiotemporally controlled release of the carried drugs in the brain; 3) Both NC and products of its degradation are biocompatible, thus limiting neurotoxicity. The biocompatibility and biodistribution of the NC will be evaluated by in-vitro, in-vivo, and ex-vivo analysis. As a proof of concept, the carrier will be loaded with active compounds and the biological effect observed will be compared with the one achieved by the free drugs. The project could have an immediate impact on NDs treatment improving the biological efficacy of the anti-prion protein drug used in this project as model drug. Such a versatile biocompatible multi-drug NC will pave the way toward a new era of NDs treatments, with a remarkable impact on society and health care systems worldwide.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores